Dendreon gets an FDA warning about promotion of Provenge

08/8/2010 | Reuters

The FDA issued a warning letter to Dendreon, saying some promotional materials for Provenge, a vaccine for prostate cancer, exaggerated benefits and minimized risks. Dendreon "intends to comply" with the FDA's request to stop using those materials, a spokeswoman said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ